Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of VAV2 in prediction of radiotherapy sensitivity and prognosis of patient

A sensitive and patient technology, applied in the field of VAV2 in predicting the radiotherapy sensitivity and prognosis of patients, it can solve the problems of poor clinical benefit, poor efficacy, and differences in the efficacy and prognosis of individual radiotherapy for esophageal cancer.

Active Publication Date: 2021-09-10
CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to the radiotherapy resistance of esophageal cancer, the final curative effect of most patients is not good, and the clinical benefit is poor
In addition, there are huge differences in the efficacy and prognosis of individual radiotherapy for esophageal cancer
However, there are currently no effective markers that can well predict the radiotherapy efficacy and clinical prognosis of esophageal cancer.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of VAV2 in prediction of radiotherapy sensitivity and prognosis of patient
  • Application of VAV2 in prediction of radiotherapy sensitivity and prognosis of patient
  • Application of VAV2 in prediction of radiotherapy sensitivity and prognosis of patient

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0156] Example 1. Screening of genes related to radiotherapy sensitivity in esophageal cancer

[0157] In order to discover genes related to radiotherapy sensitivity in esophageal cancer, the present invention uses a PDX (Patient-Derived Xenograft, PDX) mouse model derived from esophageal cancer patients. By irradiating PDX with the same dose, the radiotherapy efficacy of patients was divided into sensitive and resistant. Subsequently, combined with patient gene sequencing data, differentially expressed genes that affect radiation efficacy were discovered. And use GO enrichment analysis to verify the reliability of the experiment. The accuracy of the data in this study was verified by enrichment analysis of transcription factors in the TRRUST database.

[0158] figure 1 It is to compare the transcriptome sequencing data of the sensitive group and the resistant group, and visualize the clustering heat map of the Heatmap formed by using the R software for the differential ...

Embodiment 2

[0160] Example 2, Verification of VAV2 Overexpression Cell Line Construction by Lentivirus

[0161] Then we constructed a VAV2 overexpression cell line through lentivirus to determine whether VAV2 is related to radioresistance in gene function.

[0162] Figure 4The results of comparative experiments between control cells and cell lines overexpressing VAV2, the experiment of comparing control cells and cell lines overexpressing VAV2 through clone formation experiments, A is the plate formed after irradiating different doses of radiation, B is based on the ability of colony formation The plotted cell survival curve, p<0.05, C is the result of western experiment on the expression of VAV2 in two kinds of cells, which proves that the expression of VAV2 in the cell line overexpressing VAV2 increases.

[0163] Figure 5 The CCK-8 method is used to detect the proliferation ability of cells. The experiment found that irradiation significantly inhibited the proliferation ability o...

Embodiment 3

[0166] Example 3, siRNA interference technology knockdown VAV2 verification

[0167] In order to further verify that VAV2 is related to radiosensitivity in gene function, we used the tumor tissue derived from patients with esophageal cancer to construct the primary esophageal cancer cell line, named NCCE1, and the construction process was as follows: Figure 7 shown.

[0168] Knockdown VAV2 by siRNA interference technology, siRNA interference sequence: gggacgacaucuacgagga (SEQ IDNO: 5) The specific steps are as follows:

[0169] (1) The day before transfection, transfer the well-growing cells to a 6-well plate, with 350,000-550,000 cells per well, to ensure that the cell growth density reaches 40-60% during transfection.

[0170] (2) Before transfection, the cells were washed 3 times with PBS, and 1ml of Opti-MEM medium was added to wait for transfection.

[0171] (3) First, add an appropriate amount of siRNA to 250 μl Opti-MEM, mix gently, and incubate at room temperature...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a new application of a biomarker VAV2 in prediction of radiotherapy sensitivity or prognosis of a patient, and provides the application of an inhibitor of the VAV2 in treatment of the patient. Preferably, the patient is diagnosed to suffer from cancer; and more preferably, the patient is diagnosed to suffer from the esophageal cancer. Preferably, the treatment includes prognosis improvement and radiotherapy sensitivity improvement.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to the use of VAV2 in predicting radiotherapy sensitivity and prognosis of patients. Background technique [0002] Esophageal cancer is one of the malignant tumors with the highest mortality rate in the world. Its early diagnosis is difficult, its malignancy is high, and its prognosis is poor. The five-year survival rate is only 25-40%. The early symptoms of esophageal cancer are often not obvious, and most patients are mostly in the middle and late stages when they see a doctor, and they lose the opportunity for surgery. Comprehensive treatment based on radiotherapy is of great significance. However, due to the radiotherapy resistance of esophageal cancer, the final curative effect of most patients is not good, and the clinical benefit is poor. In addition, there are huge differences in the efficacy and prognosis of individual radiotherapy for esophageal cancer. However, there is cur...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886C12N5/10C12N15/113C12N15/867G01N33/68
CPCC12Q1/6886C12N5/0693C12N15/1135C12N15/86C07K14/47G01N33/68C12Q2600/158C12Q2600/118C12Q2600/106C12N2740/15043
Inventor 林东昕吴晨苗传望刘伟玲席奕轶陈新杰牛香洁谭文
Owner CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com